Trevi Therapeutics (TRVI) Analyst & Key Data

Analyst Consensus

Buy18 analysts

Buy

Updated Sep 12, 2026

Total Analysts18

Strong Buy

1

Buy

17

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$15.90

DCF Value-99.33%

$0.11

Potential downside vs current price

Current Stock Price

$15.90

DCF Value-99.33%

$0.11

Potential downside vs current price

Analyst Consensus

Buy18 analysts

Buy

Updated Sep 12, 2026

Total Analysts18

Strong Buy

1

Buy

17

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$15.90

DCF Value-99.33%

$0.11

Potential downside vs current price

Current Stock Price

$15.90

DCF Value-99.33%

$0.11

Potential downside vs current price

Trevi Therapeutics, Inc.